{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:29:50Z","timestamp":1793734190190,"version":"4.6.1"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:p>Retinal vascular diseases, including neovascular age-related macular degeneration, diabetic macular edema, retinal vein occlusion, myopic choroidal neovascularization, and retinopathy of prematurity, are a major cause of visual morbidity in India. Although anti-vascular endothelial growth factor (anti-VEGF) therapy has transformed the management of these conditions, long-term outcomes in real-world Indian practice are frequently limited by affordability-related undertreatment. The introduction of biosimilar anti-VEGF agents, particularly ranibizumab biosimilars, has therefore assumed critical importance in improving access to sustained retinal care. This narrative review synthesizes the available Indian evidence on the clinical efficacy, safety, immunogenicity, and cost-effectiveness of biosimilar anti-VEGF agents. A comprehensive literature search was conducted in PubMed, MEDLINE, EMBASE, and Scopus from inception through September 2025 using predefined keywords related to biosimilar ranibizumab, retinal vascular diseases, safety, immunogenicity, real-world evidence, and cost-effectiveness. Additional studies were identified through manual screening of reference lists. Peer-reviewed English-language randomized trials, phase 3 studies, post-marketing surveillance reports, and large real-world cohorts from India were included. Across major retinal indications, phase 3 trials consistently demonstrated equivalence or noninferiority of biosimilars to the reference molecule in visual and anatomical outcomes, with comparable safety and low immunogenicity. Large real-world datasets further corroborate these findings and provide reassurance regarding ophthalmic use of biosimilar anti-VEGF. Importantly, reduced treatment costs have translated into improved treatment initiation and adherence. Overall, current evidence supports biosimilar ranibizumab as a safe, effective, and cost-effective alternative for retinal diseases in resource-limited settings.<\/jats:p>","DOI":"10.4103\/ijo.ijo_3222_25","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:01:27Z","timestamp":1777478487000},"page":"760-766","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Biosimilar anti-vascular endothelial growth factor agents: Clinical outcomes, safety, and cost-effectiveness in India"],"prefix":"10.4103","volume":"74","author":[{"given":"Debdulal","family":"Chakraborty","sequence":"first","affiliation":[{"name":"Department of Vitreo-Retinal Services, Disha Eye Hospitals, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tushar Kanti","family":"Sinha","sequence":"additional","affiliation":[{"name":"Department of Vitreo-Retinal Services, Disha Eye Hospitals, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhendu","family":"Boral","sequence":"additional","affiliation":[{"name":"Department of Vitreo-Retinal Services, Disha Eye Hospitals, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnab","family":"Das","sequence":"additional","affiliation":[{"name":"Department of Vitreo-Retinal Services, Disha Eye Hospitals, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"R1-20261103","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"key":"R2-20261103","article-title":"World Population Ageing 2023: Challenges and opportunities of population ageing in the least developed countries","journal-title":"UN DESA\/POP\/2023\/TR\/NO.5"},{"key":"R3-20261103","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4103\/0301-4738.126189","article-title":"Changing paradigms of anti-VEGF in the Indian scenario","volume":"62","author":"Shanmugam","year":"2014","journal-title":"Indian J Ophthalmol"},{"key":"R4-20261103","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12939-019-1001-7","article-title":"Out-of-pocket expenditure and distress financing on institutional delivery in India","volume":"18","author":"Mishra","year":"2019","journal-title":"Int J Equity Health"},{"key":"R5-20261103","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1038\/s41433-024-03001-8","article-title":"Biosimilar ranibizumab in India- overview of phase 3 clinical trial designs","volume":"38","author":"Sharma","year":"2024","journal-title":"Eye (Lond)"},{"key":"R6-20261103","doi-asserted-by":"crossref","DOI":"10.1177\/24741264251322213","article-title":"Biosimilar Ranibizumab (Ranieyes) safety and efficacy in the real world: BRESER study","author":"Sharma","year":"2025","journal-title":"J Vitreoretin Dis"},{"key":"R7-20261103","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s40123-021-00345-2","article-title":"Real-world safety outcomes of intravitreal ranibizumab biosimilar (razumab) therapy for chorioretinal diseases","volume":"10","author":"Chakraborty","year":"2021","journal-title":"Ophthalmol Ther"},{"key":"R8-20261103","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.2147\/OPTH.S515479","article-title":"CompaRative safety analysis of innovator and BioSimilar Ranibizumab in chorioretinal vascular diseases-The CRIBS study","volume":"19","author":"Chakraborty","year":"2025","journal-title":"Clin Ophthalmol"},{"key":"R9-20261103","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.2147\/OPTH.S549744","article-title":"Biosimilar versus innovator Ranibizumab in myopic CNVM: Comparative real-world outcomes- The BRIM study","volume":"19","author":"Chakraborty","year":"2025","journal-title":"Clin Ophthalmol"},{"key":"R10-20261103","doi-asserted-by":"crossref","first-page":"820755","DOI":"10.3389\/fmed.2022.820755","article-title":"Regulatory information and guidance on biosimilars and their use across Europe: A call for strengthened one voice messaging","volume":"9","author":"Barbier","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"R11-20261103","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s40265-018-0881-y","article-title":"Switching reference medicines to biosimilars: A systematic literature review of clinical outcomes","volume":"78","author":"Cohen","year":"2018","journal-title":"Drugs"},{"key":"R12-20261103","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1080\/14712598.2025.2506445","article-title":"The conundrum of abundance: Challenges of having too many biosimilars","volume":"25","author":"Sharma","year":"2025","journal-title":"Expert Opin Biol Ther"},{"key":"R13-20261103","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s40123-024-00883-5","article-title":"Efficacy, safety and immunogenicity of Sun\u2019s Ranibizumab biosimilar in neovascular age-related macular degeneration: A phase 3, double-blind comparative study","volume":"13","author":"Ghosh","year":"2024","journal-title":"Ophthalmol Ther"},{"key":"R14-20261103","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.2147\/OPTH.S488866","article-title":"Efficacy and safety of biosimilar Ranibizumab (OPTIMAB) versus innovator Ranibizumab in patients with neovascular (Wet) age-related macular degeneration: A double-blind, randomized, multicenter, phase III study","volume":"18","author":"Rana","year":"2024","journal-title":"Clin Ophthalmol"},{"key":"R15-20261103","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.2147\/OPTH.S307746","article-title":"Randomised, double-blind, comparative clinical study of new Ranibizumab biosimilar in neovascular (Wet) age-related macular degeneration","volume":"15","author":"Apsangikar","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"R16-20261103","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000488602","article-title":"Real-life clinical effectiveness of Razumab\u00ae (the World\u2019s First Biosimilar of Ranibizumab) in retinal vein occlusion: A subgroup analysis of the pooled retrospective RE-ENACT Study","volume":"241","author":"Sharma","year":"2019","journal-title":"Ophthalmologica"},{"key":"R17-20261103","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s40123-019-00228-7","article-title":"A multicenter, retrospective study (RE-ENACT 2) on the use of Razumab\u2122 (World\u2019s First Biosimilar Ranibizumab) in wet age-related macular degeneration","volume":"9","author":"Sharma","year":"2020","journal-title":"Ophthalmol Ther"},{"key":"R18-20261103","doi-asserted-by":"crossref","first-page":"101358","DOI":"10.1016\/j.ajoc.2022.101358","article-title":"Ranizurel safety evaluation in real-world -(RaSER) study","volume":"25","author":"Sharma","year":"2022","journal-title":"Am J Ophthalmol Case Rep"},{"key":"R19-20261103","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/s41433-019-0745-z","article-title":"Immunogenicity and efficacy after switching from original Ranibizumab to a Ranibizumab biosimilar: Real-world data","volume":"34","author":"Sharma","year":"2020","journal-title":"Eye (Lond)"},{"key":"R20-20261103","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.4103\/ijo.IJO_2573_20","article-title":"Vitreoretinal Society of India practice pattern survey 2020: Medical retina","volume":"69","author":"Sheth","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"R22-20261103","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s40123-022-00507-w","article-title":"Innovator versus biosimilar Ranibizumab in polypoidal choroidal vasculopathy: Real-world evidence","volume":"11","author":"Soman","year":"2022","journal-title":"Ophthalmol Ther"},{"key":"R23-20261103","doi-asserted-by":"crossref","first-page":"411","DOI":"10.4103\/ijo.IJO_973_22","article-title":"Efficacy of a biosimilar ranibizumab monotherapy for the treatment of retinopathy of prematurity","volume":"71","author":"Prajapati","year":"2023","journal-title":"Indian J Ophthalmol"},{"key":"R24-20261103","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.2147\/OPTH.S473329","article-title":"Efficacy and safety of an Indian Bevacizumab BIOSimilar (BEVATAS) for retinal vein occlusion (BIOS-RVO Study)","volume":"18","author":"Chakraborty","year":"2024","journal-title":"Clin Ophthalmol"},{"key":"R25-20261103","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2147\/OPTH.S443104","article-title":"Efficacy of an Indian Bevacizumab BIOSimilar (BEVATAS) for type 1 and aggressive posterior retinopathy of prematurity (BIOS-ROP Study)","volume":"18","author":"Chakraborty","year":"2024","journal-title":"Clin Ophthalmol"},{"key":"R26-20261103","doi-asserted-by":"crossref","first-page":"e001205","DOI":"10.1136\/bmjophth-2022-001205","article-title":"Systematic review of efficacy and meta-analysis of safety of ranibizumab biosimilars relative to reference ranibizumab anti-VEGF therapy for nAMD treatment","volume":"8","author":"Hatamnejad","year":"2023","journal-title":"BMJ Open Ophthalmol"},{"key":"R27-20261103","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40942-021-00293-w","article-title":"Safety and efficacy of Razumab (world\u2019s first biosimilar ranibizumab) in wet age-related macular degeneration: A post-marketing, prospective ASSET study","volume":"7","author":"Sharma","year":"2021","journal-title":"Int J Retina Vitreous"},{"key":"R28-20261103","doi-asserted-by":"crossref","first-page":"329","DOI":"10.18231\/j.ijceo.2023.062","article-title":"Safety and efficacy of ranibizumab biosimilar (Razumab) as a cost-effective alternative to the innovator molecule for macular disorders in real-world","volume":"9","author":"Paliwal","year":"2023","journal-title":"Indian J Clin Exp Ophthalmol"},{"key":"R29-20261103","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s40123-024-01065-z","article-title":"Pooled multicenter safety analysis of Lupin\u2019s intravitreal biosimilar Ranibizumab (Ranieyes) in chorioretinal vascular diseases","volume":"14","author":"Chakraborty","year":"2025","journal-title":"Ophthalmol Ther"},{"key":"R30-20261103","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ajo.2020.11.017","article-title":"Biosimilars for retinal diseases: An update","volume":"224","author":"Sharma","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"R31-20261103","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.4103\/ijo.IJO_1866_19","article-title":"Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in Indian patients with retinal vein occlusion, age-related macular degeneration, and diabetic macular edema","volume":"68","author":"Kelkar","year":"2020","journal-title":"Indian J Ophthalmol"},{"key":"R33-20261103","first-page":"e101850","article-title":"switching from intravitreal Ranibizumab (Lucentis) to biosimilar Ranibizumab (Ongavia) injections: Insights from a tertiary care eye centre","volume":"18","author":"Sourla","year":"2026","journal-title":"Cureus"},{"key":"R34-20261103","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1007\/s40123-023-00715-y","article-title":"Cost-Effectiveness analysis of ranibizumab biosimilar for neovascular age-related macular degeneration in Japan","volume":"12","author":"Yanagi","year":"2023","journal-title":"Ophthalmol Ther"},{"key":"R35-20261103","doi-asserted-by":"crossref","first-page":"248","DOI":"10.4103\/ijp.ijp_58_24","article-title":"Efficacy, safety, and cost-effectiveness of biosimilars of bevacizumab in n\u00e4ive patients with diabetic macular edema","volume":"56","author":"Virani","year":"2024","journal-title":"Indian J Pharmacol"},{"key":"R36-20261103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14712598.2025.2482663","article-title":"Aflibercept biosimilars-so near, yet so far","volume":"25","author":"Sharma","year":"2025","journal-title":"Expert Opin Biol Ther"},{"key":"R37-20261103","doi-asserted-by":"crossref","first-page":"e0275611","DOI":"10.1371\/journal.pone.0275611","article-title":"Efficacy and safety of a new ranibizumab biosimilar CKD-701 using a pro re nata treatment regimen in neovascular age-related macular degeneration: A phase 3 randomized clinical trial","volume":"17","author":"Yoon","year":"2022","journal-title":"PLoS One"},{"key":"R38-20261103","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: Two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"key":"R39-20261103","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1159\/000227783","article-title":"Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration","volume":"223","author":"Landa","year":"2009","journal-title":"Ophthalmologica"},{"key":"R40-20261103","doi-asserted-by":"crossref","first-page":"e0234739","DOI":"10.1371\/journal.pone.0234739","article-title":"Real-world outcomes with ranibizumab in branch retinal vein occlusion: The prospective, global, LUMINOUS study","volume":"15","author":"Pearce","year":"2020","journal-title":"PLoS One"},{"key":"R41-20261103","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s40123-021-00362-1","article-title":"Treatment landscape of macular disorders in Indian patients with the advent of Razumab (world\u2019s first Biosimilar Ranibizumab): A comprehensive review","volume":"10","author":"Sharma","year":"2021","journal-title":"Ophthalmol Ther"},{"key":"R42-20261103","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.oret.2023.05.005","article-title":"Randomized trial of biosimilar XSB-001 versus reference Ranibizumab in patients with neovascular age-related macular degeneration","volume":"7","author":"Loewenstein","year":"2023","journal-title":"Ophthalmol Retina"},{"key":"R43-20261103","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1001\/jamaophthalmol.2023.2260","article-title":"Efficacy and safety of the aflibercept biosimilar SB15 in neovascular age-related macular degeneration: A phase 3 randomized clinical trial","volume":"141","author":"Woo","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"R44-20261103","doi-asserted-by":"crossref","DOI":"10.1038\/s41433-026-04327-1","article-title":"Aflibercept 2 mg Biosimilar (aflibercept-ayyh, Pavblu): Experience of safety in clinical settings-APEX- safety study","author":"Sharma","year":"2026","journal-title":"Eye"},{"key":"R45-20261103","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.2147\/OPTH.S524395","article-title":"Efficacy and safety of aflibercept biosimilars relative to reference aflibercept therapy for neovascular age-related macular degeneration: A systematic review and meta-analysis","volume":"19","author":"Aljuhani","year":"2025","journal-title":"Clin Ophthalmol"},{"key":"R47-20261103","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1177\/24741264251322213","article-title":"Biosimilar Ranibizumab (Ranieyes) Safety and Efficacy in the Real World: BRESER Study","volume":"9","author":"Sharma","year":"2025","journal-title":"J Vitreoretin Dis"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_3222_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:00:25Z","timestamp":1793732425000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_3222_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_3222_25","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"2025-12-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-31","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}